Although current screening with flexible sigmoidoscopy and fetal occult blood test likely reduce colon cancer mortality, it is costly and probably not as effective as one-time screening with colonoscopy for detecting and preventing cancer, as well as risk stratification for further testing and surveillance. Ideal screening would target sensitive tests at high-risk individuals. It is possible that the identification of genetic or biologic markers in the future will enable us to target screening at high-risk individuals with precision.
|Original language||English (US)|
|Number of pages||11|
|Journal||Primary Care - Clinics in Office Practice|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas
- Pharmacology (medical)